NEW YORK, NY – B2i Digital, Inc. has announced that Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is its newest Featured Company. The Sarasota, Florida-based clinical-stage biotechnology company is developing the Bisphosphocin® class, a novel group of fast-acting, broad-spectrum antimicrobials designed to combat infectious diseases and antibiotic-resistant bacterial strains. B2i Digital will promote Lakewood-Amedex's work and clinical program to its network of retail and institutional investors. A full company profile is forthcoming on the B2i Digital website at https://b2idigital.com/featured-companies.
The announcement comes as Lakewood-Amedex prepares a Phase 2a proof-of-concept trial for its lead candidate, Nu-3, a topical gel for infected diabetic foot ulcers (iDFUs). This is a critical area of unmet medical need, given the rising threat of antimicrobial resistance (AMR). David Shapiro, CEO of B2i Digital, highlighted the significance: "Antimicrobial resistance keeps narrowing the list of drugs that still work against all pathogens, and the compounds coming to replace them are mostly variations on mechanisms that bacteria have already learned to defeat. Lakewood-Amedex has spent years on a compound class that disrupts the bacterial membrane physically, and in laboratory work Nu-3 has demonstrated a high barrier to resistance."
The Bisphosphocin class works by destabilizing the bacterial cell membrane in a pH- and concentration-dependent manner, typically within one minute of exposure. Because the mechanism targets the membrane itself, Nu-3 did not induce resistance in serial passage experiments and has shown broad-spectrum in vitro activity against resistant bacteria, including MRSA. This is particularly important as the World Health Organization reports 830 million people living with diabetes, about one-third of whom will develop a diabetic foot ulcer, with roughly half of those ulcers becoming infected, and 15-20% of infections involving resistant pathogens.
Lakewood-Amedex is finalizing preparations for the Phase 2a trial, which will evaluate the safety and efficacy of Nu-3 gel at three concentrations (2%, 5%, and 10%) in patients with infected diabetic foot ulcers. The study is intended to support advancement into a larger Phase 2b trial. Notably, David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, has been appointed Study Chair and will also serve as a Scientific Advisor. The dose selection is based on preclinical data reported in July, where Nu-3 was well tolerated in an FDA-required safety study at dose levels substantially higher than those planned for Phase 2a, with very low systemic exposure and no inhibition of wound healing.
Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex, emphasized the importance of the partnership: "Our focus is on bringing the Bisphosphocin class into the clinic and generating the proof-of-concept data that will define its potential in infected diabetic foot ulcers. Working with B2i Digital gives us the opportunity to explain that science, and the milestones ahead of it, to a much broader group of investors than a company at our stage would normally reach."
The company holds an intellectual property estate of 72 issued patents and 29 pending applications, covering composition of matter, formulations, use, and process patents, with principal filings running through 2038 and recent applications through 2044. Lakewood-Amedex began trading on the Nasdaq Capital Market under the symbol LABT following a direct listing in April 2026.
B2i Digital, Inc. partners with conferences, public companies, and capital markets advisors through its Featured Conference, Featured Company, and Featured Expert programs. Its media network spans 800+ news, broadcast, and trade outlets with a combined monthly audience of over 330 million, plus 1.7 million followers, 70,000 opt-in email subscribers, and a rolodex of 235,000+ capital markets contacts. More information about B2i Digital's featured companies and conferences can be found at b2idigital.com.
